« Return to News | Clinical Intelligence

The CenterWatch Monthly, July 2013

Monday, July 1, 2013 02:01 PM

CISCRP looks inside patients’ perceptions, motives

The public’s views about the perceived safety of clinical trials and the motives of study volunteers have improved significantly during the past six years, and a large percentage of patients deemed ineligible to participate choose to take no action in finding another clinical trial. These are but a few of the findings of a new study of nearly 6,000 respondents worldwide conducted by the Center for Information & Study on Clinical Research Participation (CISCRP).

 

Strategies for finding, eliminating sites’ hidden costs

As a cottage industry, investigative sites continue to face mounting concerns about clinical trial costs which they either cannot collect or must negotiate with sponsors and CROs. These expenses can include everything from investigator meetings, IRB submissions, source documents, study preparation, site initiation and document storage, to the unexpected costs of paying staff when trials are delayed or postponed or having to wait 90 days or longer for payments from sponsors...

 

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.